https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
LSG was successfully performed in all patients. No patients were lost to follow-up. Mean excess weight loss was and 87.4% and 88.1% 1 and 2 years after LSG, respectively. Headaches totally resolved in 13 patients (93.3%) and improved in 1 (P .001). Pulsatile tinnitus (P = .013), epistaxis, visual symptoms (P .001), and papilledema (P .001) significantly resolved. Medication was stopped in 14 patients (93.3%). Two years after LSG, IIH outcomes for 7 patients reaching this time point remained unchanged. This stu
Like
Comment
Share
